Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer

Abstract

Images Figure 1 Figure 2

Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study

“…25 There also have been discrepancies in the reported frequencies of cells positive for EGFR and their distribution in previous IHC studies. The reason seems to be that antibodies that reliably detect EGFR expression in fixed and paraffinembedded pathological material have only recently become available, 26 as well as differences in scoring as described for HER-2 above. 27 Recently, Goldstein and Armin 28 noted that exclusive membrane immunoreactivity usually occurred in two morphological patterns.…”

Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system

“…Different mechanisms, like autocrine stimulation by growth factors, genetic instability or transcriptional deregulation, may be considered. Amplification of the EGFR gene has been described in gastric carcinomas, [6][7][8] but no mutations have been found so far. 9 With regard to anti-EGFR therapy, the impact of EGFR heterogeneity on the therapeutic response has to be clarified.…”

“…Amplification of the EGFR gene has been described as a rare event in gastric carcinomas. [6][7][8] Mutations in the EGFR gene have been detected in glioblastomas, breast, ovarian, prostate and lung carcinomas, 9 but so far not in gastric carcinoma. Dysregulation of the EGFR signal transduction pathway is a clinical target for anticancer therapy.…”

Insulation of a conditionally expressed transgene in an adenoviral vector

“…9 The ERBB2 gene is frequently upregulated or selectively activated in common tumours, including breast, pancreatic and gastro-intestinal tract carcinomas. [11][12][13] A 500 bp 5Ј proximal promoter element cloned upstream of a transgene has been shown to drive expression in those breast cancer cell lines which overexpress the ERBB2 oncogene. 14 This observation made it an excellent candidate for exploitation in genetic prodrug activation therapy (GPAT).…”